Khalid Abozguia is a Cardiology physician affiliated with Marshall Health. OpenAlex indexes 85 publications with 2,359 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1249 15th St Ste 4000
Huntington, WV 257013663
Telephone
304-691-8500Provider last certified this registry record 21 Dec 2021.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202596 payments
- Boston Scientific CorporationProgram year202548 payments
- Abbott LaboratoriesProgram year202525 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62%Beta blocker31.1%Metoprolol Succinate76%Sotalol9%Atenolol7%Metoprolol Tartrate5%Carvedilol4%Part D<11 patientsAntiarrhythmic25.6%Dofetilide36%Flecainide Acetate34%Amiodarone Hcl14%Multaq10%Mexiletine Hcl6%Part D<11 patients+ 3 more classes in this area
Blood & clotting
32.2%Factor Xa inhibitor32.2%Eliquis86%Xarelto14%Part D≥83 patientsAnti-infectives
4.2%Tetracycline-class Drug4.2%Doxycycline Monohydrate100%Part D≥34 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Meta-analysis of the safety of outpatient sotalol initiation in clinical practice
European Heart Journal
2025 - Brugada syndrome: a review and the role of epicardial ablation in management
The Egyptian Heart Journal
2024 - Improving outcomes in single chamber leadless pacemakers: strategies for minimizing vascular complications
BMC Cardiovascular Disorders
2023 - Deep Vein Thrombosis is Common After Cardiac Ablation and Pre-Procedural D-Dimer Could Predict Risk
Heart Lung and Circulation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”